Drugmakers yet to see gains from government's minimum import price policy

Government's Minimum Import Price (MIP) initiative to boost domestic drug makers faces a slow start. Despite setting price thresholds for key raw materials like penicillin G, industry executives report a lack of clear beneficial impact. Buyers and manufacturers are hesitant to shift to domestic suppliers at MIP-linked prices, leaving significant production capacity underutilized. Some anticipate this is a temporary phase as existing stockpiles are consumed.